Marie Louise (Marieke) De Bruin

Medicine & Life Sciences

1. Hodgkin Disease 100%
2. Marketing 80%
3. European Union 80%
4. Pharmaceutical Preparations 77%
5. Breast Neoplasms 70%
6. Pharmacovigilance 69%
7. Databases 69%
8. Drug-Related Side Effects and Adverse Reactions 68%
9. Cohort Studies 68%
10. Safety 65%
11. Biological Products 54%
12. Cardiac Arrhythmias 54%
13. Population 45%
14. Observational Studies 44%
15. Type 2 Diabetes Mellitus 44%
16. Incidence 42%
17. Radiation-Induced Neoplasms 38%
18. Insulin 37%
19. Decision Making 36%
20. Meta-Analysis 36%
21. Confidence Intervals 35%
22. Netherlands 34%
23. Survivors 33%
24. Systematic Reviews 33%
25. Rosiglitazone 32%
26. Radiotherapy 31%
27. Radiation 27%
28. Neoplasms 27%
29. Insulin Glargine 27%
30. Myocardial Infarction 26%
31. Genetic Predisposition to Disease 25%
32. Risk Assessment 25%
33. Antidepressive Agents 25%
34. Urinary Bladder Neoplasms 24%
35. Odds Ratio 24%
36. Therapeutics 24%
37. Procarbazine 23%
38. Uncertainty 23%
39. Progressive Multifocal Leukoencephalopathy 23%
40. Chronic Obstructive Pulmonary Disease 22%
41. Obstructive Lung Diseases 22%
42. Hip Fractures 22%
43. Incretins 21%
44. Sudden Cardiac Death 21%
45. Out-of-Hospital Cardiac Arrest 21%
46. Metformin 20%
47. Gastrointestinal Neoplasms 20%
48. Delivery of Health Care 19%
49. General Practice 19%
50. Heart Arrest 19%